Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 6 (June)

1. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
   Clin Cancer Res, 12(11): 3532-40. [Abstract] [Full-text]
2. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
   Cancer Res, 66(11): 5858-66. [Abstract] [Full-text]
3. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
   Cancer Res, 66(11): 5790-7. [Abstract] [Full-text]
4. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
   Crit Rev Oncol Hematol, 58(3): 242-56. [Abstract] [Full-text]
5. A common phosphotyrosine signature for the Bcr-Abl kinase.
   Blood, 107(12): 4888-97. [Abstract] [Full-text]
6. An evidence-based approach to the management of pulmonary arterial hypertension.
   Curr Opin Cardiol, 21(4): 385-92. [Abstract] [Full-text]
7. Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates.
   Nat Clin Pract Oncol, 3(6): 325-338. [Abstract] [Full-text]
8. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
   J Natl Cancer Inst, 98(11): 783-93. [Abstract] [Full-text]
9. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
   Leuk Res, 30(8): 965-70. [Abstract] [Full-text]
10. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
    Br J Cancer, 94(12): 1765-9. [Abstract] [Full-text]
11. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Proc Natl Acad Sci U S A, 103(24): 9244-9. [Abstract] [Full-text]
12. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
    Eur J Gastroenterol Hepatol, 18(7): 785-7. [Abstract] [Full-text]
13. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
    N Engl J Med, 354(24): 2542-51. [Abstract] [Full-text]
14. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    N Engl J Med, 354(24): 2531-41. [Abstract] [Full-text]
15. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    Surgery, 139(6): 806-14. [Abstract] [Full-text]
16. Rational design of inhibitors that bind to inactive kinase conformations.
    Nat Chem Biol, 2(7): 358-64. [Abstract] [Full-text]
17. New emerging drugs in soft tissue sarcoma.
    Crit Rev Oncol Hematol, 59(1): 74-84. [Abstract] [Full-text]
18. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.
    Arch Surg, 141(6): 537-43; discussion 543-4. [Abstract] [Full-text]
19. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
    Scand J Gastroenterol, 41(7): 805-11. [Abstract] [Full-text]
20. A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene.
    Biochemistry, 45(25): 7854-60. [Abstract] [Full-text]
21. Molecular Analysis of Chronic Eosinophilic Leukemia with t(4;10) Showing Good Response to Imatinib Mesylate.
    Int J Hematol, 83(5): 433-8. [Abstract] [Full-text]
22. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.
    Blood, 108(1): 319-27. [Abstract] [Full-text]
23. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
    Blood, 108(1): 286-91. [Abstract] [Full-text]
24. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
    Blood, 108(1): 28-37. [Abstract] [Full-text]
25. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
    Br J Surg, 93(7): 836-43. [Abstract] [Full-text]
26. Ongoing challenges of a global international patient assistance program.
    Ann Oncol, 17: viii43-viii46. [Abstract] [Full-text]
27. Primary primitive neuroectodermal tumour of the urinary bladder: a clinico-pathological study emphasising immunohistochemical, ultrastructural and molecular analyses.
    J Clin Pathol, 59(7): 775-8. [Abstract] [Full-text]
28. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Pharmacotherapy, 26(7): 903-7. [Abstract] [Full-text]
29. Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats.
    J Pharm Pharmacol, 58(7): 997-1000. [Abstract] [Full-text]
30. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease.
    Kidney Int, 70(1): 97-103. [Abstract] [Full-text]
31. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
    Int J Gynecol Pathol, 25(3): 288-92. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.